General
Preferred name
ursodeoxycholic acid
Synonyms
URSODIOL ()
UDCA Na ()
UDCA sodium ()
Sodium Ursodeoxycholate ()
Ursodiol sodium ()
Ursodeoxycholic Acid (sodium salt) ()
Ursodeoxycholate sodium ()
Urosiol ()
Ursodeoxycholic acid, UDCA ()
Ursodeoxycholic acid sodium ()
Ursodeoxycholic Acid-d4 ()
Ursodeoxycholate ()
Ursofalk ()
Ursonorm ()
Acide ursodeoxycholique ()
Urso Forte ()
NSC-683769 ()
Acido ursodeoxicolico ()
Cholurso ()
Urso ()
Ursodesoxycholic Acid ()
Destolit ()
Actigall ()
Urso 250 ()
Urdox ()
Ursogal ()
Ursodeoxycholic Acid MaxSpec® Standard ()
Ursodeoxycholic Acid-d4 MaxSpec® Standard ()
P&D ID
PD002830
CAS
128-13-2
108609-27-4
2898-95-5
347841-46-7
Tags
available
drug
Approved by
FDA
First approval
1987
Drug indication
Primary biliary cirrhosis
Liver disease
Drug Status
approved
investigational
Max Phase
4.0
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
PHARMACODYNAMICS Ursodiol (commonly known as ursodeoxycholic acid) is a product of metabolism of bacteria in the intestine. It is considered a secondary bile acid. The other type of bile acid, primary bile acids, are produced hepatically and subsequently stored in the gallbladder. When primary bile acids are secreted into the large intestine, they can be broken down into secondary bile acids by bacteria present in the intestine. Both types of bile acids assist in the metabolism of dietary fat. Ursodeoxycholic acid regulates cholesterol levels by slowing the rate at which the intestine is able to absorb cholesterol and also acts to break down micelles, which contain cholesterol. Because of this property, ursodeoxycholic acid is used to treat gall stones non-surgically.
MOA Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells.; The main mechanism if anticholelithic. Although the exact process of ursodiol's anticholelithic action is not completely understood, it is thought that the drug is concentrated in bile and decreases biliary cholesterol by suppressing hepatic synthesis and secretion of cholesterol and by inhibiting its intestinal absorption. The reduced cholesterol saturation permits the gradual solubilization of cholesterol from gallstones, resulting in their eventual dissolution.; ; ;
INDICATION The drug decreases the absorption of cholesterol and is used to dissolve (cholesterol) gallstones in patients as an alternative to a surgical procedure to remove the gallstones.
DESCRIPTION Ursodeoxycholic acid (UDCA) acts as an antagonist of the bile acid receptor farnesoid X receptor (FXR) .

SARS-CoV-2 and COVID-19: ACE2's presence on host cells confers susceptibility to SARS-CoV-2 infection. UDCA attenuates bile acid-induced, FXR-mediated upregulation of ACE2 expression in vitro and in vivo . For this effect, UDCA has been proposed as a repurposing drug with antiviral potential against SARS-CoV-2. It is hypothesised that UDCA would reduce SARS-CoV-2 infection potential by lowering the number of ACE2 binding sites on relevant tissues. In support of this theory, a correlation between UDCA treatment for liver conditions and a lower risk of developing severe COVID-19 has been identified,

Ursodeoxycholic acid is found in large quantities in bear bile and this results in the practice of 'farming' bears for bile extraction, in some countries. (GtoPdb)
PRICE 29
DESCRIPTION Ursodeoxycholic acid is a bile acid used for the treatment of primary biliary cirrhosis, dissolution of radiolucent gallstones in patients with a functioning gallbladder, and treatment of hepatobiliary disorders associated with cystic fibrosis in pediatric patients. Ursodeoxycholic acid reduces elevated liver enzyme levels by facilitating bile flow through the liver and protecting liver cells. (Enamine Bioactive Compounds)
DESCRIPTION Ursodeoxycholic acid sodium (Sodium Ursodeoxycholate) is a naturally occurring secondary bile acid with anti-inflammatory and cytoprotective activities. Ursodeoxycholic acid sodium acts as signaling molecule, exerting its effects by interacting with bile acid activated receptors, (TargetMol Bioactive Compound Library)
Compound Sets
23
Cayman Chemical Bioactives
31016
31367
21892
31368
15121
ChEMBL Approved Drugs
CHEMBL1551
ChEMBL Drugs
CHEMBL1551
Concise Guide to Pharmacology 2023/24
7104
Drug Repurposing Hub
DrugBank
DB01586
DrugBank Approved Drugs
DB01586
DrugCentral
2797
DrugCentral Approved Drugs
2797
DrugMAP
DMCUT21
DrugMAP Approved Drugs
DMCUT21
Enamine Bioactive Compounds
EBC-11069
Enamine BioReference Compounds
EUbOPEN Chemogenomics Library
EUB0001177
Guide to Pharmacology
7104
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL1551
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Ursodiol(Actigal)
TargetMol Bioactive Compound Library
T29078
External IDs
75
Properties
(calculated by RDKit )
Molecular Weight
392.29
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
4
Ring Count
4
Aromatic Ring Count
0
cLogP
4.48
TPSA
77.76
Fraction CSP3
0.96
Chiral centers
10.0
Largest ring
6.0
QED
0.66
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target
Microbial Metabolite
TGR5
FXR
AKR1C2, NR1H4
Member status
member
MOA
Nuclear Factor, Erythroid Derived 2, Like 2 (Nrf2) Activators
Antioxidants
AKR1C3 inhibitor
nuclear factor erythroid derived, like (NRF2) activator
Indication
gallstones
Pathway
GPCR/G protein
Metabolism
Therapeutic Class
Cholagogues and Choleretics
Recommended Cell Concentration
10 uM
Source data